Loading data for ENSC — first visit, this takes a few seconds.

Alert

Ensysce Biosciences Inc. (ENSC)

NasdaqCM: ENSC · Real-Time Price · USD

0.37

-0.01 (-2.63%)

At close: Aug 21, 2026, 8:00 PM

0.36

-2.73%

After-hours: 7:36 PM

The price, the headline numbers and the latest news, in one place.

-2.63% (1D)

No data available

Bid	0.26
Market Cap	7.26M
Revenue (ttm)	4.5M
Net Income (ttm)	-12.62M
	n/a
	-2.52
	n/a
	-7.47
P/B (ttm)	-7.78
P/S (ttm)	1.61
Earnings Date	Aug 14, 2025

Ask	0.47
Volume	745,500
Avg. Volume (20D)	14,858,179
Open	0.37
Previous Close	0.38
Day's Range	0.36 - 0.37
52-Week Range	0.23 - 2.75
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About ENSC

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug t...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 14, 2018

Employees 8

Stock Exchange NasdaqCM

Ticker Symbol ENSC

Website https://www.ensysce.com

Full Company Profile

Financial Performance

In 2025, Ensysce Biosciences's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -10.18M, an increase of 27.4%.

Financial Statements

Earnings Surprise

Ensysce Biosciences has released their quarterly earnings on Aug 13, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.
EPS of -0.2 exceeds estimates by 0.30, with 74.68% YoY growth.

Next Earnings Release

Ensysce Biosciences Inc. is scheduled to release its earnings on Aug 14, 2025, after market closes.
Analysts project revenue of ... Upgrade

News

2 weeks ago · InvestorsHub

Ensysce Biosciences Completes Cy Biopharma Acquisition and Secures Up to $77 Million Private Financing

The transaction adds a clinical-stage pain therapy with FDA Orphan Drug Designation while providing funding expected to support development through Phase 2 data and into registrational planning. Key I...

1 month ago · InvestorsHub

Ensysce Biosciences Receives Final $5.3 Million NIDA Funding Installment for PF614-MPAR Development

Ensysce Biosciences (NASDAQ:ENSC) has received a $5. 3 million award from the National Institute on Drug Abuse (NIDA), completing a multi-year federal grant totaling $15.

5 months ago · MT Newswires

Update: Wall Street Set to Open Lower Friday as Investors Analyze Higher Than Expected Producer Prices; Oil Prices Surge

(Updates to add ticker symbols in the symbol box.) US stocks look set to open lower in Friday's

5 months ago · Associated Press Finance

BC-Most Active Stocks

Elong Power Holding Ltd. 27,481,598 0.1358

5 months ago · MT Newswires

Wall Street Set to Open Lower Friday as Investors Analyze Higher Than Expected Producer Prices; Oil Prices Surge

US stocks look set to open lower in Friday's trading session as investors analyze higher-than-expect

Ensysce Biosciences Inc. (ENSC)